Aquestive Therapeutics Inc
NASDAQ:AQST 3:59:59 PM EDT
Products
Aquestive Therapeutics Receives FDA Fast Track Designation For AQST-109
Published: 03/17/2022 13:37 GMT
Aquestive Therapeutics Inc (AQST) - Aquestive Therapeutics Receives FDA Fast Track Designation for Aqst-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis.
Aquestive Therapeutics Receives FDA Fast Track Designation for Aqst-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis.
Aquestive Therapeutics Inc - Expects to Report Topline Results for Full Epiphast Study in First Half of 2022.
Aquestive Therapeutics Receives FDA Fast Track Designation for Aqst-109 for Emergency Treatment of Allergic Reactions Including Anaphylaxis.
Aquestive Therapeutics Inc - Expects to Report Topline Results for Full Epiphast Study in First Half of 2022.